Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is currently in phase II clinical trials as an anticancer agent. We show in this study that R-Roscovitine can downregulate nuclear factor-kappa B (NF-jB) activation in response to tumor necrosis factor (TNF)a and interleukin 1. Activation of p53-dependent transcription is not compromised when RRoscovitine is combined with TNFa. We characterize the molecular mechanism governing NF-jB repression and show that RRoscovitine inhibits the IjB kinase (IKK) kinase activity, which leads to defective IjBa phosphorylation, degradation and hence nuclear function of NF-jB. We further show that the downregulation of the NF-jB pathway is also at the level of p65 modification and that the phosphorylation of p65 at Ser 536 is repressed by R-Roscovitine. Consistent with repression of canonical IKK signaling pathway, the induction of NF-jB target genes monocyte chemoattractant protein, intercellular adhesion molecule-1, cyclooxygenase-2 and IL-8 is also inhibited by R-Roscovitine. We further show that treatment of cells with TNFa and RRoscovitine causes potentiation of cell death. Based on these results, we suggest the potential use of R-Roscovitine as a bitargeted anticancer drug that functions by simultaneously causing p53 activation and NF-jB suppression. This study also provides mechanistic insight into the molecular mechanism of action of R-Roscovitine, thereby possibly explaining its antiinflammatory properties. The p53 and nuclear factor-kappa B (NF-kB) pathways are two critical transcriptional regulatory networks deregulated in various human ailments including cancer and there has been a lot of evidence of cross-talk between these two pathways.
The p53 and nuclear factor-kappa B (NF-kB) pathways are two critical transcriptional regulatory networks deregulated in various human ailments including cancer and there has been a lot of evidence of cross-talk between these two pathways. 1 Activation of p53 is associated with cell cycle arrest and apoptosis while NF-kB activation is associated with cell survival. Hence, the cross-talk between these pathways must be finely tuned and regulated.
p53 is one of the most extensively studied tumor suppressor proteins. 2 Loss or mutation of p53 function is correlated with increased cancer susceptibility. Hence, activating p53 has been a goal of several small molecule inhibitors currently being evaluated in the clinic.
NF-kB is a transcription factor critical for the control of inflammation, apoptosis and cell proliferation. 3, 4 Chronic inflammation by constitutively active NF-kB has been shown to contribute to the development of many cancers. 5 It is becoming apparent that deregulated activity of NF-kB is observed and causally linked to the development of several diseases that have an inflammatory component. 6, 7 Hence, identification of NF-kB inhibitors has been the focus of several academic and pharmaceutical establishments. 6, 7 Since p53 promotes cell death and NF-kB prevents cell death, an anticancer agent that simultaneously activates p53 and inhibits NF-kB would offer greater potential to target two cancer targets positively.
One of the ways in which the p53 pathway has been successfully targeted is by using cyclin-dependent kinase (CDK) inhibitors for treating various cancers, either as single agents or in combination with other drugs. Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analogue that is currently in phase II clinical trials as an anticancer agent. It competes with ATP to bind to the active site on CDKs and it was recently shown that R-Roscovitine inhibits RNA polymerase-II-dependent transcription and downregulates Mcl-1, leading to apoptosis. 8 R-Roscovitine has been shown to repress inhibition of p53 by Mdm2 and thereby activate p53 by blocking its degradation. 9 Disruption of the nucleolus to stabilize p53 has also been proposed as another alternate mechanism to activate p53. 10 R-Roscovitine has also been shown to inhibit retinoblastoma protein phosphorylation, decrease levels of cyclin D1 protein and activate the mitogen-activated protein kinase pathway. 11 These studies provide information on the cellular pharmacology of the drug and are a good source of pharmacodynamic markers in the development of the drug in the clinic. R-Roscovitine has been proposed for combination chemotherapy by affecting DNA repair, apoptosis and having a chemoprotective effect. 12 It has been reported to have antitumor activity against several cancer cell lines. 11, 13, 14 It can also induce apoptosis in multiple myeloma cells, 15 primary B-cell chronic lymphatic leukemia cells 16 and also maturing cerebellar granule neurons. 17 Another study demonstrated the ability of RRoscovitine to promote resolution of inflammation and inflammatory cell apoptosis associated with the loss of expression of Mcl-1. 18 This was further confirmed in mouse models of bleomycin-induced lung injury; carrageenan elicited acute pleurisy and passively induced arthritis, thereby suggesting its potential use for treating various inflammatory diseases. R-Roscovitine was also reported to effectively arrest cystic disease in mouse models of polycystic kidney disease (PKD), thereby suggesting its potential use in the treatment of PKD. 19 Thus, there is considerable interest in elucidating the mechanism of action of R-Roscovitine to help in its evaluation as a potential drug for use in the clinic.
In this study, we show that R-Roscovitine can inhibit activation of NF-kB. While the NF-kB pathway is repressed, activation of p53 is not compromised, suggesting its potential to target both these critical cancer targets simultaneously. We characterize the molecular mechanism underlying its action. Our results provide deeper insight into the cellular pharmacology of R-Roscovitine and could also help to explain its antiinflammatory effects.
Results
R-Roscovitine represses TNFa-induced activation of NF-jB in a dose-dependent manner. Since the NF-kB pathway has been shown to be a target for anti-inflammatory molecules, 20 we checked whether R-Roscovitine, which has anti-inflammatory properties, 18 has any effect on the NF-kB pathway. For this, A549-NF-kB-luc (A549) and 293-NF-kBluc (293) cells were treated with different concentrations of RRoscovitine (5, 10, 15 and 30 mM). Both the cell lines used are stable cell lines derived from human A549 and 293 cells, respectively, with chromosomal integration of a luciferase reporter construct regulated by six copies of the NF-kB response element (Panomics). A549 cells show optimum NF-kB activation when incubated with 50 ng/ml tumor necrosis factor (TNF)a for 6 h, while 293 cells show optimum activation when treated with 20 ng/ml TNFa for 8 h before luciferase activity is read (Panomics).
We used a concentration range of R-Roscovitine that has been previously shown to increase p53-dependent transcription, 8 and found that R-Roscovitine inhibits TNFa-induced activation of NF-kB reporter in a dose-dependent manner ( Figure 1a, lanes 6-10) . The results were further confirmed in 293 cells (Figure 1b, lanes 6-10) . We conclude that R-Roscovitine inhibits the activation of NF-kB in a dosedependent manner.
p53 activation is not compromised upon combination of R-Roscovitine with TNFa. It is known that R-Roscovitine activates p53-dependent transcription. 8, 9 We next tested whether the suppression of TNFa-induced activation of NF-kB after treatment with R-Roscovitine was at the expense of p53 pathway activation. As shown in Figure 2a (lanes 3,4) , treating cells with R-Roscovitine or its combination with TNFa showed a significant increase in p53 protein levels, while treatment of A549 cells with TNFa alone did not show any increase ( Figure 2a , lane 2). We also tested if the treatment had any effect on p53 modifications. As shown in Figure 2a (lanes 3-4), simultaneous treatment with R-Roscovitine and TNFa for 12 h showed an increase in phosphorylation of both Ser392 and Ser15 and also acetylation of p53. p53 activation (Figure 2a ) was further confirmed by using a cell-based reporter assay in ARN8 human melanoma cells which measures induction of p53 transcriptional activity. 21 Treatment of cells with R-Roscovitine alone induces p53-dependent transcription, while treatment of cells with TNFa alone shows no activation (Figure 2b ). However, a similar degree of p53 activation is still maintained when the cells are simultaneously treated with R-Roscovitine and TNFa. This was further confirmed by quantitative RT-PCR for p53 target genes (Figure 2c) . Treatment of cells with R-Roscovitine and TNFa showed an increase in mRNA levels of p53 target genes like p21 and p53-upregulated modulator of apoptosis (PUMA). We thus conclude that p53 activation is not compromised upon combination of R-Roscovitine and TNFa.
R-Roscovitine inhibits NF-jB target genes. TNFa has been shown to upregulate levels of NF-kB target genes like intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase 
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We assessed whether R-Roscovitine could downregulate these endogenous NF-kB target genes in a manner similar to its repression of the NF-kB reporter gene activity ( Figure 1 ). Figure 3a and b (lanes 7-10) document that R-Roscovitine repressed the expression of NF-kB gene products ICAM-1, monocyte chemoattractant protein (MCP-1), Bcl-xL and FLIP in both A549 and H1299 cells. To validate if this repression occurred at the level of transcription, we carried out quantitative RT-PCRs. We show that downregulation of NF-kB targets MCP-1, Cox-2 and IL8 in both A549 and H1299 cells indeed occurred at the level of transcription (Figure 3c-e) . Besides TNFa, NF-kB activity is also induced by inflammatory cytokines like interleukin 1 (IL1). 26 We found that R-Roscovitine strikingly inhibits NF-kB targets ICAM-1 and MCP-1 induced by IL1 as well (Figure 3f ). Taken together, we believe that R-Roscovitine could be used as a potent inhibitor of NF-kB signaling. Figure 2a) . RRoscovitine treatment alone decreased levels of IkBa, 24 h after treatment. In all our time course studies, cells were pretreated with R-Roscovitine for 12 h followed by a timedependent treatment with TNFa. Hence at the final time points, cells were exposed to R-Roscovitine for about (Figure 4g and h, lanes [1] [2] [3] [4] [5] shows that treatment with TNFa alone decreases levels of IkBa after 30 min, which is restored to starting levels in a time-dependent manner. Upon treatment with R-Roscovitine, even though the starting levels of IkBa are lower, TNFa treatment did not cause degradation and re-synthesis of IkBa (Figure 4g and h, lanes 7-10). Furthermore, there was no effect on IkBa levels upon treatment with R-Roscovitine alone in either IKK1 or IKK2 knockout MEFs ( Supplementary  Figure 2b) , indicating that R-Roscovitine-mediated lowering of IkBa levels could be cell type specific and is not the only cause of reduced IkBa levels seen in some of our assays. Taken together, our results demonstrate that apart from exerting its effect on other pathways, R-Roscovitine is a potent inhibitor of IKK activity and hence the NF-kB pathway.
R-Roscovitine inhibits
R-Roscovitine inhibits TNFa-induced p65 Ser536 phosphorylation. TNFa-induced phosphorylation of p65 is critical for NF-kB transcription. 28 To further understand the mechanism of NF-kB repression by R-Roscovitine, we assessed the levels of p65 phosphorylation and other critical components of the NF-kB pathway. As shown in Figure 4e and f, R-Roscovitine significantly downregulates TNFa-induced activation of p65 phosphorylation at Ser536 (compare lanes 1-6 and 7-10). A similar decrease in phosphorylation is seen in p65 phosphorylation at Ser276; however, the effect is less pronounced than phosphorylation at Ser536. These effects are seen in both A549 and H1299 cells, further supporting our results that downregulation of the NF-kB pathway by R-Roscovitine is independent of the status of p53 in the cells. Given that serine 536 is considered a bona fide IKK site, these results are consistent with R-Roscovitine being an inhibitor of canonical IKK signaling.
R-Roscovitine represses TNFa-induced p65 nuclear localization. Since nuclear localization of the p65 subunit is critical for NF-kB function, we next checked if RRoscovitine affects this process. R-Roscovitine inhibits TNFa-induced nuclear accumulation of p65 at all the time points tested (Figures 5 and 6 ). This effect is seen in both A549 and H1299 cells. Taken together, the results presented thus far indicate that R-Roscovitine is an inhibitor of IKK kinase activity. Inhibition of this activity leads to loss of IkB degradation and consequently leads to loss of modification and nuclear accumulation of NF-kB.
R-Roscovitine potentiates cytotoxic effects of TNFa. It has been shown that TNFa induces apoptosis if NF-kB is repressed. 29 Since R-Roscovitine can inhibit NF-kB, we also Figure 4e and f investigated if combining R-Roscovitine and TNFa could lead to TNFa-induced cell death. Using annexin V staining as a marker for cell death, we observed that R-Roscovitine potentiated TNFa-induced cell death in a concentrationand time-dependent manner in both A549 and H1299 cells (Figure 7a and b, compare lanes 1-6) . Furthermore, combination of R-Roscovitine and TNFa for 12 h caused a significant increase in PARP cleavage, another hallmark of apoptosis (Figure 7c, lane 4) . R-Roscovitine alone has been shown to induce PARP cleavage. 8 Treatment of A549 cells with R-Roscovitine alone induces PARP cleavage only after 24 h (Figure 7d , lane 6), further supporting that R-Roscovitine potentiates cytotoxic effects of TNFa. Thus, we believe that R-Roscovitine is a useful agent that can block critical physiological functions of NF-kB. cases, in combination with nongenotoxic agents. 30 A model based on our study is presented in Figure 8 . In this study, we have shown that R-Roscovitine inhibits TNFa-induced NF-kB pathway through inhibition of the IKK kinase activity and phosphorylation and degradation of IkBa. Furthermore, we show that it prevents nuclear accumulation of p65 and downregulates phosphorylation of p65 at a crucial serine 536 residue, which is required for chromatin remodeling. Consistent with being a potent inhibitor of NF-kB, RRoscovitine also potentiates apoptosis induced by TNFa and downregulates expression of NF-kB target genes. Finally, we demonstrate that R-Roscovitine can also inhibit NF-kBdependent gene activation in response to other stimuli such as IL1 (Figure 3f) .
Clinical use of TNFa as a single agent has been extremely limited due to its severe side effects. 31 It is becoming increasingly evident that the best strategy to use in cancer chemotherapy is a combination of known drugs that synergistically act on various pathways and targets simultaneously. This is also emerging as an improved means of combating the problem of drug resistance and improving the efficiency of therapeutic response to tumors. Our studies suggest the Inhibition of transcription has been predicted to sensitize cancer cells to TNFa. This has been reported for flavopiridol, 32 a semisynthetic flavonoid and another potent inhibitor of cyclin-dependent kinases CDK1, CDK2, CDK4 and CDK7. 33 Previous studies showing very strong cytotoxicity of flavopiridol in combination with either TNFa or tumor necrosis factorrelated apoptosis inducing ligand (TRAIL) have been very encouraging. While most efforts towards understanding the mechanism of action of flavopiridol have focused on the p53 pathway, work by Takada and Aggarwal 34 showed that flavopiridol has the additional property of inhibiting TNFainduced activation of NF-kB in a dose-dependent manner. It does so by inhibiting IkBa kinase, a key NF-kB regulator, and affecting its critical post-translational modifications including its degradation by ubiquitination. Flavopiridol also affects nuclear localization of p65 and inhibits NF-kB target genes like cyclin D1, thereby inhibiting inflammation and modulating cell growth. 34 We see similar effects with R-Roscovitine on the NF-kB pathway. Both R-Roscovitine and flavopiridol are CDK inhibitors that suppress general transcription and paradoxically activate p53-dependent transcription. We show in this study that R-Roscovitine activates p53-dependent transcription even when combined with TNFa, and potentiates TNFainduced apoptosis in a dose-and time-dependent manner. We also show in this study that the effect of R-Roscovitine on the NF-kB pathway is independent of p53, further suggesting its potential to target both these pathways simultaneously, regardless of the p53 status in tumors. It is possible that, since R-Roscovitine potentiates cell death independently of p53 (Figure 7a and b) , the pathway involving the interaction of Fas-associated death domain (FADD) and the mitochondrial caspase cascade is involved. 31 Furthermore, our study is focused on the mechanism of action of R-Roscovitine in lung cancer cells, where current clinical trials are focused (Appraise trial, Cyclacel, http://www.cyclacel.com/cyc/rd/trials/).
A recent study 35 showed that nuclear expression of p65 was significantly increased in both small-cell and non-small cell lung cancers, thereby suggesting that inflammation could have a potential role in the early pathogenesis of lung cancer. Thus, R-Roscovitine could have therapeutic applications in this context as well. We have shown in this study that RRoscovitine inhibits TNFa-induced activation of NF-kB target genes involved in antiapoptosis (Bcl-xL and FLIP), proliferation (Cox-2) and invasion of tumors (ICAM-1) (Figure 3a and b) .
Earlier studies have shown that R-Roscovitine induces apoptosis by inhibiting RNA polymerase II (Pol II)-dependent transcription and downregulating genes involved in cell survival. 8, 16 Consistent with their studies, we also see downregulation of total Pol II and Ser2 phosphorylation upon treatment with R-Roscovitine (Supplementary data 1) . However, our data also support specific effects of R-Roscovitine on inhibiting TNFa-induced activation of the NF-kB pathway. Our reporter assay (Figure 1) shows that R-Roscovitine only inhibits TNFa-induced activation. While levels of IkBa are downregulated upon long exposure to R-Roscovitine, no effect is seen on levels of IkBa in other cells like the IKK1 and IKK2 knockout MEFs. Thus, while inhibition of Pol II transcription by R-Roscovitine could be a contributor to NF-kB inhibition, the effect we report cannot be completely explained by a general downregulation of Pol II-dependent transcription by R-Roscovitine.
It is interesting to note that the protein levels of both IkBa and Bcl-xL are decreased in A549 cells upon treatment with R-Roscovitine for 24 h (Supplementary data 2 and 3) . This is not an effect of general transcription inhibition since a similar effect is not seen in MEFs or IKK knockout cells. A very interesting study by Junan Li et al., 36 showed that IkBa binds CDK4 and inhibits its activity. They proposed a functional cross-talk between the NF-kB pathway and the p16-CDK4-Rb pathway. While our results show that R-Roscovitine inhibits the NF-kB pathway and IkBa protein levels at longer time points, R-Roscovitine has also been shown to inhibit Rb protein phosphorylation. 11 This further suggests the cross-talk between these signaling pathways and suggests that R-Roscovitine could be targeting both these pathways by affecting IkBa. Further studies would be aimed at better understanding the mechanism of this functional cross-talk and its molecular pharmacology to aid development of R-Roscovitine in the clinic. Another recent work by Komarova et.al. 37 showed p53 as a suppressor of inflammatory response in mice and proposed a general 'buffering' role of these reciprocally controlled pathways. This 'pharmacological tuning', as proposed by them, would offer the potential of targeting both the pathways in one attempt. Quinacrine, an anti-malarial drug, and flavopiridol have also been shown to have both these desirable properties. 38 Finally, our study shows that R-Roscovitine inhibits the NF-kB pathway, thereby possibly explaining its anti-inflammatory properties. We show that it downregulates NF-kB gene targets involved in antiapoptosis, cell invasion and proliferation ( Figure 8 ). Current studies are underway to further delineate the targets of R-Roscovitine and their effects on various signaling pathways. This study provides the scientific rationale for combination therapy with R-Roscovitine and also suggests biomarkers for effects of R-Roscovitine and possibly other CDK inhibitors currently in the clinic for the management of lung cancer. It would also be worthwhile to get a deeper insight into the mechanism of action of RRoscovitine in combination with NF-kB inhibitors in the clinic. Thus, R-Roscovitine has the potential to simultaneously benefit two critical targets in cancer in a desirable way: activation of p53 and suppression of NF-kB. This would be particularly useful in cancers where NF-kB is constitutively active, thereby maintaining p53 in a repressed state. We further propose a thorough clinical evaluation of this approach.
Materials and Methods
Cell culture, cell lines and reagents. A549-NF-kB-luc (A549) and 293-NF-kB-luc (293) were purchased from Panomics Inc. Both cell lines were cultured at 371C and 5% CO 2 in DMEM medium supplemented with 10% FBS, L-glutamine, penicillin and streptomycin and were maintained in selection medium containing HygromycinB. ARN8 human melanoma cells and H1299 (p53-null) human nonsmall-cell lung carcinoma cells were cultured in DMEM medium supplemented with 10% FBS, penicillin and streptomycin. R-Roscovitine was purchased from Calbiochem and TNFa was purchased from Sigma.
NF-jB reporter activity assay. A549-NF-kB-luc (A549) and 293-NF-kB-luc (293) cells were seeded in 96-well plates at 10 000 cells/well. Cells were treated with different concentrations of the drugs as mentioned for different time intervals. The luciferase activity was measured using the Bright-Glot luciferase assay system (Promega) and the assay was performed as per the manufacturer's instructions. The fold activation or repression was calculated relative to the control sample and all measurements were done by calculating the average of triplicate samples of two independent experiments. p53 reporter activity assay. The p53 reporter activity assay was a cellbased reporter assay developed in ARN8 cells. The details of the reporter system have been described elsewhere. 21 The assay was performed in 96-well plates and the cells were seeded and treated as described above. The FluoReporter LacZ/ Galactosidase quantitation kit was used to measure fluorescence with excitation at 390 nm and emission at 460 nm. SpectraMAX (Molecular Probes) was used to measure fluorescence readings. Since IkBa bound p65 is not modified and since RRoscovitine-mediated inhibition of IKK blocks its activity, the phosphorylation of p65 at serine 536 is also affected by this treatment (since it is an IKK site). R-Roscovitine treatment eventually prevents the nuclear localization of p65 and thereby downregulates the NF-kB pathway and its various gene products involved in cell invasion, cell proliferation and antiapoptosis propidium iodide binding assay (Roche). The extent of apoptosis was quantified as a percentage of annexin V-positive cells over the total cell population. Flow cytometric analysis was performed on an LSR II system (BD Biosciences).
Western blot analysis. Cells were seeded at 1 Â 10 6 cells/ml and treated with 30 mM R-Roscovitine and 50 ng/ml TNFa. Before harvesting, cells were washed twice with PBS. The pellet was split for use for western blot analysis and quantitative RT-PCR. Cells were lysed on ice in RIPA buffer with 2 Â protease inhibitor cocktail (Roche) and the protein concentration was determined using the Bradford reagent (Bio-Rad). In total, 30 mg of lysate in SDS gel loading buffer and 10 mM DTT was separated on 4-12% Bis-Tris gels (Invitrogen). Proteins were transferred onto nitrocellulose membrane (Bio-Rad) and equal loading confirmed by Ponceau S staining (Sigma). The membrane was blocked in 5% milk in PBS with 0.1% Tween-20 (PBST) for 1 h and incubated overnight with primary antibody at 41C. Membranes were washed with PBST and then incubated in horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Membranes were washed again for 1 h with PBST and developed using ECL detection reagents (Amersham). Antibodies were used to detect p53 (DO-1), p21, PUMA (Calbiochem), p65, IkBa, ICAM-1, MCP-1 (Santa Cruz Biotechnology, Santa Cruz, CA), Acetylated p53, p65-Ser536, p65-ser276, p-IkBa, PARP, p53-Ser15, p53-Ser392, Bcl-xL, FLIP (Cell Signaling Technology) and Beta-actin (Sigma).
IKK kinase activity assay. IKK kinase activity was performed as described previously. 39 The cDNA coding for the first 54 amino acids of IkBa was isolated by PCR from total MEF cDNA and cloned into pOPTG expression vector as a GST fusion gene. The GST-IkBa (1-54aa) fusion protein was expressed in RIPL bacteria, purified on glutathione sepharose beads (GE Healthcare) and used in the kinase assay.
Quantitative RT-PCR. Cells were treated and harvested in the same way as for western blot studies. Total RNA was isolated using the RNeasy kits (Qiagen). The RNA was quantitated by spectrophotometric analysis and used for quantitative RT-PCR. The primers used for each target analyzed are available upon request. The power SYBR green PCR master mix (Applied Biosystems) was used for quantitation of mRNA levels.
Immunostaining and fluorescence microscopy. Indirect immunofluorescence was carried out as described previously. 40 DO-1 (anti-p53), p65 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-mouse Alexa-488-coupled secondary antibody (Molecular Probes) were used. Immunofluorescence was visualized using AxioImager Z1 (Zeiss).
